Facet by the Numbers | Q3-2024
Total ESG submissions to FDA July – September 2024: Over [...]
New Draft FDA Guidance: Chemical Analysis for Biocompatibility Assessment of Medical Devices (September 20, 2024)
FDA issued a draft guidance for industry and FDA staff [...]
New FDA Guidance: Control of Nitrosamine Impurities in Human Drugs (September 2024)
FDA issued Revision 2 of the guidance for industry Control [...]
Director Jeff Shuren, CDRH Retires
On July 23, 2024, Jeff Shuren, Director of the Center [...]
Gene Therapies in the Spotlight – A Major Trend in 2024
Cellular and gene therapies are one of the hottest product [...]
Update on BIOSECURE Act
On September 9, 2024, the House of Representatives passed the [...]
Recent Facet Successes – Just a Few Highlights (Q3-2024)
Facet Helps Small Biologics Company Secure Breakthrough Designation on Phase [...]
Facet Life Sciences Quarterly Newsletter Q3-2024
Recent Facet Successes - Just a Few Highlights Facet Helps [...]
gET sOCIAL